Changes in the use of radiation therapy for early classical Hodgkin lymphoma in adolescents and young adults: implications for survival and second malignancies

References

• Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007;25:3495–3502.
   PubMed Web of Science ®Google Scholar
• Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916–1927.
   PubMed Web of Science ®Google Scholar
• Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640–652.
   PubMed Web of Science ®Google Scholar
• Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431–3439.
   PubMed Web of Science ®Google Scholar
• Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012;366:399–408.
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Canc Netw 2011;9:1020–1058.
   PubMed Web of Science ®Google Scholar
• Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011;117:1806–1816.
   PubMed Web of Science ®Google Scholar
• R Foundation. R: a language and environment for statistical computing. Version 2.13.2. Vienna, Austria: R Project for Statistical Computing; 2011.
   Google Scholar
• Gray RJ. cmprsk: subdistribution analysis of competing risks. R Package Version 2.2-2. Vienna, Austria: R Project for Statistical Computing; 2011.
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2011, based on November 2013 SEER data submission. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2011/
   Google Scholar
• Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21:4386–4394.
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011;29:4096–4104.
   PubMed Web of Science ®Google Scholar
• Brusamolino E, Anselmo AP, Klersy C, et al. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study. Haematologica 1998;83:812–823.
   PubMed Web of Science ®Google Scholar
• Koontz MZ, Horning SJ, Balise R, et al. Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol 2013;31:592–598.
   PubMed Web of Science ®Google Scholar
• Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128–3135.
   PubMed Web of Science ®Google Scholar
• Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma (HL). J Clin Oncol 2005;23(Suppl.): Abstract 6505.
   PubMed Web of Science ®Google Scholar
• Cella DF, Orav EJ, Kornblith AB, et al. Socioeconomic status and cancer survival. J Clin Oncol 1991;9:1500–1509.
   PubMed Web of Science ®Google Scholar
• Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604–1608.
   PubMed Web of Science ®Google Scholar
• Koshy M, Rich SE, Mahmood U, et al. Declining use of radiotherapy in stage I and II Hodgkin's disease and its effect on survival and secondary malignancies. Int J Radiat Oncol Biol Phys 2012;82:619–625.
   PubMed Web of Science ®Google Scholar
• Travis LB, Hill DA, Dores GM, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465–475.
   PubMed Web of Science ®Google Scholar
• Dorffel W, Ruhl U, Luders H, et al. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95. J Clin Oncol 2013;31:1562–1568.
   PubMed Web of Science ®Google Scholar
• Raemaekers JM, Andre MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2014;32:1188–1194.
   PubMed Web of Science ®Google Scholar
• Radford J, Barrington S, Counsell N, et al. Involved field radiotherapy versus no further treatment in patients with clinica stage IA and IIA Hodgkin lymphoma and a “negative” PET scan after 3 cycles of ABVD. Results of the UK NCRI RAPID trial. Blood 2012; 120(Suppl. 1): Abstract 547.
   Google Scholar